News

Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been

There's a disconnect between AT&T (NYSE: T) the stock and AT&T the company. While investors have punished the telecom stock over the past few years, sending shares down about 30% since the start of

Abbott Laboratories (NYSE: ABT) is a longtime leader in the healthcare industry. The medical device specialist has been around for decades, delivering solid returns to its loyal shareholders

AbbVie (NYSE: ABBV) is a top pharmaceutical company with a broad mix of products in its portfolio. It also pays an attractive dividend, which yields 4% -- that's more than twice the S&P 500 average

Big pharma is facing another round of major patent expirations. Before the decade's end, Bristol Myers Squibb (BMS) will lose exclusivity for the megablockbuster blood thinner Eliquis as well as its

Growth stocks get the designation because they have the potential to generate life-changing gains for investors. Some even do so in a relatively short time frame. Finding proper growth stocks

There are many ways to grow one's wealth over a decade, but few are as accessible as investing in stocks. Even with a relatively modest sum, picking the right investments and letting time and

Dividends are nice. But do you know what's even nicer? Fast-growing dividends. That's especially true with inflation eroding the purchasing power of your money.

The good news for income investors is

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550

No person knows for sure what the future will hold for stocks in the new year. However, it can be fun to attempt to predict what might happen.

Three Fool.com contributors have done just that. Here's

Inflation is arguably the top economic story of the last couple of years. Indeed, consumer purchasing power is down 16% since the beginning of 2020. That means $1,500 would only buy $1,260 worth of

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex

Dividend stocks can be incredible investments. They've historically outperformed the market over the long term. The best returns have come from companies that routinely increase their dividends.

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.

Three Motley Fool contributors think

While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable

Shares of Coherus BioSciences (NASDAQ: CHRS) are up 19.7% as of 3:20 p.m. ET Thursday after the U.S. Food and Drug Administration (FDA) approved Udenyca OnBody, the company's on-body injection

Biotech stocks are often challenging for investors to evaluate without having a full scientific context, and Sarepta Therapeutics (NASDAQ: SRPT) is no exception. With multiple successful products on

Fool.com contributor Parkev Tatevosian compares Ford (NYSE: F) and AT&T (NYSE: T) on vital financial metrics to determine the better dividend stock to buy for 2024.

*Stock prices used were the

Telecom giant AT&T (NYSE: T) is vastly underperforming the S&P 500 in 2023. With just a few trading days left in the year, AT&T stock is down nearly 10% year to date while the S&P 500 has gained

You might call it a "Pfizzle."

In late 2021, Pfizer (NYSE: PFE) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.

It followed